MedCity News

Anterior Snags $40M to Speed Care Approvals with AI

PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug

PTC Therapeutics said it cannot resolve differences it has with the FDA in interpreting clinical trial data for Translarna, a drug it developed for Duchenne muscular dystrophy. The rare disease drug developer’s decision to withdraw Translarna’s FDA submission comes nearly a year after a negative European regulatory decision for the drug.

By Frank Vinluan

MedCity Influencers

Closing the CKD Care Gap with Value-Based Care Models

VBC models deliver significant benefits for CKD management by coordinating medical, behavioral, and social support through multidisciplinary teams. This approach enables providers to personalize care, address barriers to access, and use data-driven strategies to identify and prioritize high-risk patients.

By Heather Trafton

MedCity Influencers

AI Can’t Improve Healthcare if Clinicians and Staff Aren’t Trained to Use, Orchestrate It

Giving healthcare teams powerful AI tools without training undermines their ability to use potentially system-changing tools safely and effectively.

By Matt Scavetta

Latest Video

Latest News

BioPharma, Artificial Intelligence

COO of Mayo Clinic Platform Believes De-identified Data Leads to Loss of Utility for Pharma, Other Third Parties

Mayo Clinic has about 100 petabytes of structured and unstructured EHR data, and about 28 petabytes have been de-identified, but in the Mayo Clinic way. Now that data capability is being combined with institutional expertise to provide a compelling case for pharma companies looking to leverage data, AI and provider expertise in drug development.

By Arundhati Parmar

BioPharma, Pharma

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for later this year.

By Frank Vinluan

The Power of One: Redefining Healthcare with an AI-Driven Unified Platform

In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.

By David Cohen, Chief Product & Technology Officer, Greenway Health

Health Tech, Startups, Providers

Female psychotherapist talking with a man via online video chat. Psychologist conducting an online therapy session with her patient.

Talkiatry Rakes In $210M to Scale Virtual Psychiatry Group

Telepsychiatry provider Talkiatry has raised a $210 million Series D round led by Perceptive Advisors, bringing its total funding to more than $400 million. CEO Robert Krayn said the company is focused on scaling its clinician-employed model and improving outcomes as competition intensifies across behavioral health and virtual care.

By Katie Adams

MedCity Influencers

Empathetic AI Nurses Can Vastly Improve Nurses’ Work and Patient Care

The AI revolution doesn't mean erasing the value of humans. It means giving nurses more time to do what they signed up to do — deliver care directly to patients.

By Tomas Gorny

MedCity Influencers

Blinded by Science: The Importance of RWD and Post-market Surveillance

When applied with a rigorous, subject-matter-expert guided process, AI-currated RWD is an essential resource giving life science organizations new power to monitor the diverse variety of ways drugs are actually utilized post-approval.

By Sujay Jadhav

Artificial Intelligence, Hospitals, Startups, Health Tech

Female worker turning to face the camera while sitting in the office of a clinical analysis laboratory

Why Mount Sinai Chose Microsoft Over Abridge and Suki

Mount Sinai Health System is betting on Microsoft’s Dragon Copilot as its ambient scribing tool of choice, a decision that followed competitive tests against rival vendors Abridge and Suki. Lisa Stump, Mount Sinai’s chief digital information officer, noted that the health system has been transparent with Microsoft that their partnership may change given Epic’s launch of a built-in AI charting tool earlier this month.

By Katie Adams

BioPharma, Legal

Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance

The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company said the agency’s justification for refusing a review is inconsistent with guidance given prior to the start of Phase 3 testing.

By Frank Vinluan

MedCity Influencers

AI-powered creative writing and education concept. Futuristic chatbot with digital pencil. Smart learning, content creation, and automation. Modern vector illustration on dark blue background

From Claims Payer to Care Partner: What AI Really Changes in Health Insurance, and What It Doesn’t

AI can help health plans reduce friction, speed revenue-cycle throughput, and improve member experience, but only when it is deployed with strong data discipline, modern integration patterns, and a governance model that treats AI as “augmented intelligence,” meaning powerful, assistive, and accountable.

By Chris House

MedCity Influencers

The Next Frontier of Interoperability: Additional Clinical Data Sources – Dentistry, Devices, Social Care, and More

Healthcare cannot achieve its goals for quality, equity, and value without breaking down the persistent barriers that keep critical information siloed across sectors.

By Steven Lane

MedCity Influencers

Medicare Advantage’s Discipline Era — and Why the Final Rate Notice Matters More Than It Appears

The challenge for policymakers is balance: encouraging rigor without unintentionally weakening a program that now serves the majority of Medicare beneficiaries. Thoughtful rate calibration can determine whether this transition strengthens the program or strains it unnecessarily.

By Sachin H. Jain

BioPharma, Pharma

Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis

Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent.

By Frank Vinluan

Artificial Intelligence

A mechanical hand with dots hovering over it and a pill showing AI and medicine

Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery

Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.

By Arundhati Parmar